13.04.2012 - Finland is the last Nordic country which has not yet decided to start a nationwide bioeconomy programme. Calls for such an strategy are becoming louder.
Helsinki – Denmark has already implemented a national bioeconomy strategy, investing €1.8bn by 2015. At the end of March, Norway and Sweden announced at the "Bioeconomy in Action" conference that they would also start countrywide efforts. Norway intends to spend as much as €300m in total. Demands for Finland not to fall behind are becoming more pressing. Erkki KM Leppävuori, President and CEO of the VTT Technical Research Centre of Finland, said during a conference on April 12, "Finland should create a national bioeconomy strategy as soon as possible". According to Leppävuori, bioeconomy has all the prerequisites for creating a radical increase in the value of exports and for developing into a new pillar of support for wellbeing in Finland. "This will require the making of choices, the taking of risks, and the development and marketing of bioeconomy-based technologies", he added. Finland’s forest industry especially might profit from such a move. According to expert assessment, by 2020 new technological solutions and diversification could raise Finland's production by €6bn (equal to an increase of 22% compared to the 2010 level). Current operations could be expanded into the production of composites, biofuels and biochemicals, and into service businesses. Leppävuori already has a suggestion for facilitating the necessary changes, "The renewal of Finland’s business sector can be expedited by forming a voluntary partnership network – the Finnish Institute of Technology and Innovation (FIT). Research programs in the network could be opened up to each other and large-scale multidisciplinary projects initiated in applied research." Leppävuori added, "This is also a question of effective utilization of Finland’s limited research resources."
03.07.2015 Biotech giant Biogen is investing CHF 1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, the new plant will create up to 400 jobs.
02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.
30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.
24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.
22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.
12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.
METTLER TOLEDO now offers a new family of high-precision weighing platforms that provide superior accuracy and reliability in harsh industrial conditions with flexibility to be used for many applications. more